Sort
4,870 grants matching “glp 1”
DEVELOPMENT OF AN ORAL DRUG FOR SMALLPOX TREATMENT
$8,477,202Chimerix, Inc. · U01 · FY2005 · AI
DEVELOPMENT OF AN ORAL DRUG FOR SMALLPOX TREATMENT
$8,448,207George R Painter · Chimerix, Inc. · U01 · FY2007 · AI
NIAAA Repository/Screening Database Management and Research
$8,273,144Melanie Schwandt · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2019 · AA
Development of a monoclonal antibody to reverse overdose from fentanyl and its analogs: from manufacturing to clinical trials
$8,267,350Marco Pravetoni · University Of Washington · UG3 · FY2022 · DA
UPR Center for Incubator and Technology Transfer (UPRCITT)
$7,897,996Jose A Lasalde-Dominicci · University Of Puerto Rico · C06 · FY2023 · OD
DEVELOPMENT OF AN ORAL DRUG FOR SMALLPOX TREATMENT
$7,747,639Chimerix, Inc. · U01 · FY2004 · AI
HVTN Laboratory Program
$7,256,662Margaret Juliana McElrath · Fred Hutchinson Cancer Research Center · UM1 · FY2013 · AI
National Islet Cell Consortium Coordinating Center
$7,212,659City Of Hope/Beckman Research Institute · U42 · FY2003 · RR
Continuation of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study
$7,183,299John M Lachin · George Washington University · U01 · FY2021 · DK
A once-weekly oral methadone for maintenance therapy for opioid use disorder
$6,854,394Stephen Zale · Lyndra Therapeutics, Inc. · UG3 · FY2019 · DA
An Intranasal GDNF Gene Therapy for Opioid Relapse Reduction
$6,693,512Barbara Lee Waszczak · Northeastern University · UG3 · FY2021 · DA
Clinical Development of a Dengue Vaccine
$6,565,626Hawaii Biotech, Inc. · UC1 · FY2004 · AI
NIAAA Repository/Screening Database Management and Research
$6,533,330Melanie Schwandt · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2018 · AA
NIAAA Repository/Screening Database Management and Research
$5,788,835Melanie Schwandt · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2022 · AA
An ultra-long-acting oral treatment for opioid use disorder
$5,658,273Patrick Boen · Lyndra Therapeutics, Inc. · UG3 · FY2019 · DA
Core--Vector
$5,492,013Jaap Goudsmit · Beth Israel Deaconess Medical Center · U19 · FY2006 · AI
Evaluation of Optimized Lead Candidates for Encephalitic Alphaviruses in Animal Models
$5,425,184Colleen B Jonsson · University Of Tennessee Health Sci Ctr · U19 · FY2023 · AI
NIAAA Repository/Screening Database Management and Research
$5,170,949Melanie Schwandt · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2021 · AA
Silence ALS: A Platform for the Discovery and Development of Antisense Therapeutics for Patients with Ultra-Rare Forms of ALS
$5,159,965Neil Alan Shneider · Columbia University Health Sciences · U01 · FY2024 · NS
Development of SBI-553, an allosteric modulator of NTR1, for the treatment of substance use disorders
$5,014,452Michael Jackson · Sanford Burnham Prebys Medical Discovery Institute · UH3 · FY2023 · DA
IID Vaccine Evaluation and Development
$5,000,000David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2014 · CA
Development of Alphavirus Replicon Vaccine Against SARS
$4,839,367Alphavax Human Vaccines, Inc. · UC1 · FY2004 · AI
First-In-Human Study of a Humanized Anti-Cocaine Monoclonal Antibody
$4,770,702Andrew B Norman · University Of Cincinnati · U01 · FY2019 · DA
Preclinical Development of Non-Invasive Anthrax Vaccine
$4,698,162Ligocyte Pharmaceuticals, Inc. · UC1 · FY2005 · AI
Silence ALS: A Platform for the Discovery and Development of Antisense Therapeutics for Patients with Ultra-Rare Forms of ALS
$4,636,637Neil Alan Shneider · Columbia University Health Sciences · U01 · FY2025 · NS